High doses of antiviral drug may be effective against Ebola

March 27, 2018, Public Library of Science
Ebola
Ebola virus. Credit: NIAID

High doses of favipiravir extended survival in non-human primates infected with Ebola virus, according to a new study published this week in PLOS Medicine by Jeremie Guedj of INSERM, France, and colleagues.

Despite repeated outbreaks in recent years, there is no effective treatment validated for patients with Ebola virus disease, which can kill about half of those infected. The antiviral drug favipiravir has been previously tested at lower doses in humans and was well-tolerated but did not show strong antiviral activity. In the current study, researchers infected 26 non-human primates with the 2001 Gabon strain of Ebola virus and followed them for 21 days. Thirteen animals were untreated and 13 were treated, beginning two days before infection, with twice daily doses of favipiravir at 100, 150, or 180 mg/kg.

All animals that were untreated or treated with 100 mg/kg of favipiravir died within 10 days of infection. Two out of 5 (40%) animals treated with 150 mg/kg were still alive at day 21 of the study, and 3 out of 5 animals (60%) treated with 180 mg/kg favipiravir survived to day 21. Moreover, the study showed that the drug inhibited viral replication in a drug concentration-dependent manner. However, applicability to humans is limited by the fact that this model is fully lethal and that treatment initiation in patients is most often initiated several days after infection, when symptoms and high levels of are already present, rather than before infection.

"These results, together with previous data collected on tolerance and pharmacokinetics in both and humans support the evaluation of high doses of favipiravir for future human intervention in particular for contact cases" the authors say.

Explore further: Antiviral favipiravir successfully treats Lassa virus in guinea pigs

More information: Guedj J, Piorkowski G, Jacquot F, Madelain V, Nguyen THT, Rodallec A, et al. (2018) Antiviral efficacy of favipiravir against Ebola virus: A translational study in cynomolgus macaques. PLoS Med 15(3): e1002535. doi.org/10.1371/journal.pmed.1002535

Related Stories

Antiviral favipiravir successfully treats Lassa virus in guinea pigs

October 13, 2015
Favipiravir, an investigational antiviral drug currently being tested in West Africa as a treatment for Ebola virus disease, effectively treated Lassa virus infection in guinea pigs, according to a new study from National ...

Limited promise in early results from Ebola drug trial

February 24, 2015
Early results from an Ebola trial using the experimental drug Avigan (favipiravir) showed Monday it was somewhat effective at saving lives if given early in the illness, but not later.

Nuanced findings for a large experimental treatment trial for Ebola virus disease

March 1, 2016
While not conclusive, valuable research generated through researching an experimental treatment for Ebola virus disease in Guinea during the recent Ebola outbreak will support future research into treating Ebola virus disease, ...

Japan ready to offer flu drug for Ebola treatment (Update)

August 25, 2014
Japan said Monday it is ready to provide a Japanese-developed anti-influenza drug as a possible treatment for the rapidly expanding Ebola outbreak.

Researchers develop Ebola treatment effective three days after infection

April 22, 2015
Researchers from The University of Texas Medical Branch at Galveston and Tekmira Pharmaceuticals Corp., have successfully developed a post-exposure treatment that is effective against a specific strain of the Ebola virus ...

Drug targeting Ebola virus protein VP24 shows promise in monkeys

February 10, 2015
An experimental medication that targets a protein in Ebola virus called VP24 protected 75% of a group of monkeys that were studied from Ebola virus infection, according to new research conducted by the U.S. Army, in collaboration ...

Recommended for you

Breakthrough in designing a better Salmonella vaccine

September 24, 2018
UC Davis researchers announce in the Proceedings of the National Academy of Sciences this week a breakthrough in understanding which cells afford optimal protection against Salmonella infection—a critical step in developing ...

Antifungal agent found to be possible treatment for porphyria

September 24, 2018
A large team of researchers from Spain, France and the U.S. has found that a common antifungal agent might be useful as a treatment for a rare type of porphyria. In their paper published in the journal Science Translational ...

New findings on the muscle disease Laing early-onset distal myopathy

September 24, 2018
New avenues are now being opened toward treatment of Laing distal myopathy, a rare disorder that causes atrophy of the muscles in the feet, hands and elsewhere. In a study published in the journal PNAS, researchers have identified ...

Insulin shows great potential against chronic colitis

September 24, 2018
Diabetes is not the only disease on which insulin has an effect, it appears. In a new study using tests on mice, researchers from the University of Copenhagen, among others, have discovered a new method for treating chronic ...

A new approach to developing a vaccine against vivax malaria

September 21, 2018
A novel study reports an innovative approach for developing a vaccine against Plasmodium vivax, the most prevalent human malaria parasite outside sub-Saharan Africa. The study led by Hernando A. del Portillo and Carmen Fernandez-Becerra, ...

Pre-clinical success for a universal flu vaccine offers hope for third generation approach

September 21, 2018
Researchers from the University of Oxford's Department of Zoology have demonstrated pre-clinical success for a universal flu vaccine in a new paper published in Nature Communications.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.